Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957473 | 0.90 | HTR6 (0.66) | HTR6HTR2BDRD2HTR7 | |
| SCHEMBL3948503 | 0.89 | HTR6 (0.52) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL8250729 | 0.85 | HTR6 (0.52) | HTR6HTR2BDRD2HTR2CHTR7 | |
| Hydrochloric Acid SCHEMBL3949180 | 0.84 | HTR6 (0.52) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL3951523 | 0.80 | HTR6 (0.58) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL3949533 | 0.80 | HTR6 (0.62) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL3949874 | 0.79 | HTR6 (0.68) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL3949862 | 0.79 | HTR6 (0.51) | HTR6 | |
| SCHEMBL3948910 | 0.79 | HTR6 (0.67) | HTR6HTR2BDRD2HTR2CHTR7 | |
| SCHEMBL14037408 | 0.77 | HTR6 (0.57) | HTR6HTR2BDRD2HTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | claimed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7560470-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| US-7238696-B2 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232618-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR2C, HTR3B | HTR6 1/4885HTR2B 14/4885DRD2 158/4885 |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | HTR6 1/4885HTR2B 14/4885DRD2 158/4885 |
| US-20040167122-A1 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR2C | HTR6 1/4885HTR2B 16/4885DRD2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.